Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:indanes
go back to main search page
Accession:CHEBI:46940 term browser browse the term


show annotations for term's descendants           Sort by:
 
aprindine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace2 angiotensin I converting enzyme 2 increases activity ISO Aprindine results in increased activity of ACE2 protein CTD PMID:21859683 NCBI chr  X:32,050,734...32,095,860
Ensembl chr  X:32,049,931...32,096,016
JBrowse link
G Cat catalase decreases expression ISO Aprindine results in decreased expression of CAT protein CTD PMID:1937386 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Drd1 dopamine receptor D1 affects binding ISO Aprindine binds to DRD1 protein CTD PMID:9808703 NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
JBrowse link
G Drd2 dopamine receptor D2 affects binding ISO Aprindine binds to DRD2 protein CTD PMID:9808703 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Aprindine results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 affects response to substance ISO KCNQ1 gene affects the susceptibility to Aprindine CTD PMID:15028050 NCBI chr 1:216,293,087...216,630,339
Ensembl chr 1:216,293,087...216,630,339
JBrowse link
bromindione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO bromindione inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
enrasentan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ednra endothelin receptor type A multiple interactions ISO enrasentan binds to and results in decreased activity of EDNRA protein CTD PMID:16219361 NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO enrasentan binds to and results in decreased activity of EDNRB protein CTD PMID:16219361 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
JBrowse link
fluindione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Vkorc1 vitamin K epoxide reductase complex, subunit 1 decreases activity
multiple interactions
ISO fluindione results in decreased activity of VKORC1 protein
fluindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide]
CTD PMID:29581108 NCBI chr 1:199,338,785...199,341,306
Ensembl chr 1:199,337,138...199,341,302
JBrowse link
G Vkorc1l1 vitamin K epoxide reductase complex, subunit 1-like 1 multiple interactions
decreases activity
ISO fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide]
fluindione results in decreased activity of VKORC1L1 protein
CTD PMID:29581108 NCBI chr12:30,218,825...30,268,990
Ensembl chr12:30,222,701...30,268,990
JBrowse link
ICI 118551 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO ICI 118551 inhibits the reaction [Formoterol Fumarate results in decreased expression of ACTA2 protein] CTD PMID:21603974 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Adrb1 adrenoceptor beta 1 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB1 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB1 protein]
[Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]
CTD PMID:9260993 PMID:14730417 PMID:19719783 NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions
affects binding
ISO
EXP
[ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased susceptibility to Nicotine; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein]
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which affects the uptake of Levodopa; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Levodopa]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Terbutaline results in increased activity of ADRB2 protein]
ICI 118551 inhibits the reaction [[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose]; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]; ICI 118551 inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; ICI 118551 inhibits the reaction [Isoproterenol results in increased activity of ADRB2 protein]
CTD PMID:2462161 PMID:7969507 PMID:9260993 PMID:10344530 PMID:10372227 PMID:10455254 PMID:10894789 PMID:10952688 PMID:11096136 PMID:12198331 PMID:12535855 PMID:12608646 PMID:12920204 PMID:14730417 PMID:16036225 PMID:17003101 PMID:17369603 PMID:17925438 PMID:18552870 PMID:18820136 PMID:20054151 PMID:20590644 PMID:24705868 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
JBrowse link
G Adrb3 adrenoceptor beta 3 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB3 protein; ICI 118551 binds to and results in increased activity of ADRB3 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB3 protein]
[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein
CTD PMID:1682311 PMID:14730417 PMID:19719783 NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
JBrowse link
G Agt angiotensinogen multiple interactions ISO ICI 118551 inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]] CTD PMID:7843740 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA] CTD PMID:16036225 NCBI chr 9:94,189,961...94,193,054
Ensembl chr 9:94,190,067...94,192,813
JBrowse link
G Arrb2 arrestin, beta 2 multiple interactions ISO ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]] CTD PMID:17925438 NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [ICI 118551 co-treated with gemcitabine] results in increased expression of BAX protein CTD PMID:21570961 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [ICI 118551 co-treated with gemcitabine] results in decreased expression of BCL2 protein CTD PMID:21570961 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions EXP capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein] CTD PMID:14764656 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Calcb calcitonin-related polypeptide, beta multiple interactions EXP capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein] CTD PMID:14764656 NCBI chr 1:184,271,116...184,276,480
Ensembl chr 1:184,271,590...184,276,475
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO ICI 118551 inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] CTD PMID:22167199 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Edn1 endothelin 1 multiple interactions ISO ICI 118551 inhibits the reaction [olodaterol results in decreased expression of EDN1 mRNA] CTD PMID:22796455 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Gnas GNAS complex locus multiple interactions
increases expression
ISO [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein
ICI 118551 results in increased expression of GNAS protein
CTD PMID:10455254 NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483
Ensembl chr 3:172,374,957...172,428,483
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 increases expression
multiple interactions
ISO ICI 118551 results in increased expression of GRK2 protein
[ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein
CTD PMID:10455254 NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
JBrowse link
G Il18 interleukin 18 multiple interactions ISO ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 mRNA]; ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 protein] CTD PMID:15178407 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il5 interleukin 5 multiple interactions ISO ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]] CTD PMID:16238794 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Il6 interleukin 6 multiple interactions EXP ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Terbutaline promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] CTD PMID:9688336 PMID:10525314 PMID:11096136 PMID:12619890 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 multiple interactions
decreases activity
ISO ICI 118551 results in decreased activity of [KCNH2 protein binds to KCNH2 protein]
ICI 118551 results in decreased activity of KCNH2 protein
CTD PMID:15679475 PMID:16314852 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]]
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK1 protein]]
CTD PMID:11675405 PMID:12608646 PMID:17003101 PMID:17925438 PMID:19719783 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]]
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK3 protein]]
CTD PMID:11675405 PMID:12608646 PMID:17003101 PMID:17925438 PMID:19719783 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions EXP [Dobutamine co-treated with ICI 118551] results in increased activity of MAPK9 protein CTD PMID:19719783 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression
decreases secretion
ISO ICI 118551 results in decreased expression of MMP2 mRNA; ICI 118551 results in decreased expression of MMP2 protein
ICI 118551 results in decreased secretion of MMP2 protein
CTD PMID:20424515 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression
decreases secretion
ISO ICI 118551 results in decreased expression of MMP9 mRNA; ICI 118551 results in decreased expression of MMP9 protein
ICI 118551 results in decreased secretion of MMP9 protein
CTD PMID:20424515 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression ISO ICI 118551 results in decreased expression of PPARGC1A mRNA CTD PMID:17446185 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression
multiple interactions
ISO ICI 118551 results in decreased expression of PTGS2 mRNA; ICI 118551 results in decreased expression of PTGS2 protein
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]
CTD PMID:17003101 PMID:17369603 PMID:20424515 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO ICI 118551 inhibits the reaction [Albuterol results in decreased expression of RB1 protein] CTD PMID:16446544 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Ren renin multiple interactions ISO ICI 118551 inhibits the reaction [Epinephrine results in increased activity of REN protein] CTD PMID:6314140 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]]
ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
CTD PMID:9688336 PMID:10525314 PMID:10857765 PMID:11096136 PMID:11675405 PMID:15081246 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO ICI 118551 results in decreased expression of VEGFA mRNA; ICI 118551 results in decreased expression of VEGFA protein CTD PMID:20424515 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
indan-1-ol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1b10 aldo-keto reductase family 1 member B10 increases oxidation ISO AKR1B10 protein results in increased oxidation of 1-indanol CTD PMID:19013440 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 multiple interactions EXP [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-indanol CTD PMID:18845131 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases oxidation ISO AKR1C4 protein results in increased oxidation of 1-indanol CTD PMID:8543560 NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
JBrowse link
indane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO indan results in decreased activity of CYP1A2 protein CTD PMID:15916432 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
Indanofan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO indanofan binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
pevonedistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bbc3 Bcl-2 binding component 3 affects expression ISO pevonedistat affects the expression of BBC3 mRNA CTD PMID:24634471 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression ISO pevonedistat affects the expression of BCL2 mRNA CTD PMID:24634471 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 affects expression ISO pevonedistat affects the expression of BCL2L1 mRNA CTD PMID:24634471 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 affects expression ISO pevonedistat affects the expression of BCL2L11 mRNA; pevonedistat affects the expression of BCL2L11 protein CTD PMID:24634471 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Casp3 caspase 3 multiple interactions ISO pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22110742 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl17 C-C motif chemokine ligand 17 affects expression ISO pevonedistat affects the expression of CCL17 mRNA CTD PMID:24634471 NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
JBrowse link
G Ccl22 C-C motif chemokine ligand 22 affects expression ISO pevonedistat affects the expression of CCL22 mRNA CTD PMID:24634471 NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 affects expression ISO pevonedistat affects the expression of CCL5 mRNA CTD PMID:24634471 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccnd1 cyclin D1 affects expression ISO pevonedistat affects the expression of CCND1 mRNA CTD PMID:24634471 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 affects expression ISO pevonedistat affects the expression of CCND2 mRNA CTD PMID:24634471 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Cd40 CD40 molecule affects expression ISO pevonedistat affects the expression of CD40 mRNA CTD PMID:24634471 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cd74 CD74 molecule affects expression ISO pevonedistat affects the expression of CD74 mRNA CTD PMID:24634471 NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 increases abundance ISO pevonedistat results in increased abundance of CDT1 protein CTD PMID:22110742 NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression ISO pevonedistat affects the expression of CFLAR mRNA CTD PMID:24634471 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Ctnnb1 catenin beta 1 increases abundance ISO pevonedistat results in increased abundance of CTNNB1 protein CTD PMID:22110742 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cul1 cullin 1 decreases metabolic processing ISO pevonedistat results in decreased metabolism of CUL1 protein CTD PMID:22110742 NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 affects expression ISO pevonedistat affects the expression of CXCL9 mRNA CTD PMID:24634471 NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
JBrowse link
G Cxcr3 C-X-C motif chemokine receptor 3 affects expression ISO pevonedistat affects the expression of CXCR3 mRNA CTD PMID:24634471 NCBI chr  X:71,614,346...71,616,997
Ensembl chr  X:71,614,346...71,616,997
JBrowse link
G Cxcr5 C-X-C motif chemokine receptor 5 affects expression ISO pevonedistat affects the expression of CXCR5 mRNA CTD PMID:24634471 NCBI chr 8:48,835,688...48,852,032
Ensembl chr 8:48,836,957...48,850,671
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta affects expression ISO pevonedistat affects the expression of GADD45B mRNA CTD PMID:24634471 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases abundance
multiple interactions
ISO pevonedistat results in increased abundance of JUN protein
Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]
CTD PMID:22110742 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III increases expression ISO pevonedistat results in increased expression of MAF1 protein CTD PMID:31645432 NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
JBrowse link
G Mir155hg Mir155 host gene affects expression ISO pevonedistat affects the expression of MIR155HG mRNA CTD PMID:24634471 NCBI chr11:24,175,417...24,177,646 JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO pevonedistat results in increased expression of MYC protein CTD PMID:25897075 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 affects activity ISO pevonedistat affects the activity of NFKB1 protein CTD PMID:24634471 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation ISO pevonedistat results in increased phosphorylation of NFKBIA protein CTD PMID:22110742 PMID:24634471 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO pevonedistat results in increased cleavage of PARP1 protein
pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]
CTD PMID:22110742 PMID:24634471 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases abundance
affects expression
multiple interactions
ISO pevonedistat results in increased abundance of PMAIP1 protein
pevonedistat affects the expression of PMAIP1 mRNA
Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]
CTD PMID:22110742 PMID:24634471 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects activity ISO pevonedistat affects the activity of RELA protein CTD PMID:24634471 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 increases expression ISO pevonedistat results in increased expression of RICTOR protein CTD PMID:25897075 NCBI chr 2:56,013,898...56,105,818
Ensembl chr 2:56,052,643...56,101,803
JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 increases expression ISO pevonedistat results in increased expression of RPTOR protein CTD PMID:25897075 NCBI chr10:108,750,620...109,058,691
Ensembl chr10:108,750,620...109,058,691
JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein] CTD PMID:30067223 NCBI chr 3:165,520,155...165,538,176
Ensembl chr 3:165,520,392...165,537,940
JBrowse link
G Stat5a signal transducer and activator of transcription 5A affects expression ISO pevonedistat affects the expression of STAT5A mRNA CTD PMID:24634471 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Uba3 ubiquitin-like modifier activating enzyme 3 decreases activity ISO pevonedistat results in decreased activity of UBA3 protein CTD PMID:22110742 NCBI chr 4:129,548,411...129,569,550
Ensembl chr 4:129,548,416...129,569,470
JBrowse link
G Wee1 WEE1 G2 checkpoint kinase increases abundance ISO pevonedistat results in increased abundance of WEE1 protein CTD PMID:22110742 NCBI chr 1:174,765,228...174,790,882
Ensembl chr 1:174,767,960...174,786,361
JBrowse link
phenindione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I; [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I metabolite CTD PMID:21613233 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Tp53 tumor protein p53 increases degradation ISO Phenindione results in increased degradation of TP53 protein CTD PMID:14634213 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Vkorc1 vitamin K epoxide reductase complex, subunit 1 decreases activity
multiple interactions
ISO Phenindione results in decreased activity of VKORC1 protein
Phenindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]
CTD PMID:29581108 NCBI chr 1:199,338,785...199,341,306
Ensembl chr 1:199,337,138...199,341,302
JBrowse link
G Vkorc1l1 vitamin K epoxide reductase complex, subunit 1-like 1 multiple interactions
decreases activity
ISO Phenindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]
Phenindione results in decreased activity of VKORC1L1 protein
CTD PMID:29581108 NCBI chr12:30,218,825...30,268,990
Ensembl chr12:30,222,701...30,268,990
JBrowse link
rasagiline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gdnf glial cell derived neurotrophic factor multiple interactions
increases expression
ISO Sulfasalazine inhibits the reaction [rasagiline results in increased expression of GDNF protein]
rasagiline results in increased expression of GDNF mRNA; rasagiline results in increased expression of GDNF protein
CTD PMID:14687604 NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
JBrowse link
G Maob monoamine oxidase B decreases activity ISO rasagiline results in decreased activity of MAOB protein CTD PMID:21923181 NCBI chr  X:6,430,694...6,533,520
Ensembl chr  X:6,430,594...6,533,534
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO rasagiline results in increased localization of and results in increased activity of RELA protein; Sulfasalazine inhibits the reaction [rasagiline results in increased localization of and results in increased activity of RELA protein] CTD PMID:14687604 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19883
    chemical entity 19883
      molecular entity 19880
        polyatomic entity 19794
          molecule 19628
            cyclic compound 19446
              bicyclic compound 16944
                carbobicyclic compound 5818
                  indanes 83
                    (1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine 0
                    (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-2-phenylmethyl-4-hydroxy-5-[(2S)-4-(benzofuran-2-ylmethyl)-2-(tert-butylaminocarbonyl)piperazin-1-yl]pentanamide 0
                    (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-5-[(2S)-2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(phenylmethyl)pentanamide 0
                    (3R)-tetrahydrofuran-3-yl [(1S,2S)-1-benzyl-3-\{(2S)-2-benzyl-4-[(1R,2R)-2-(carbamoyloxy)-2,3-dihydro-1H-inden-1-yl]-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-2-hydroxypropyl]carbamate 0
                    (3S)-tetrahydrofuran-3-yl [(1S,2S)-3-\{(2S)-4-[(1R,3R)-3-(2-amino-2-oxoethyl)-2,3-dihydro-1H-inden-1-yl]-2-benzyl-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-1-benzyl-2-hydroxypropyl]carbamate 0
                    (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-3-(methylsulfonyl)-L-alanyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                    (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                    (R)-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                    (S,S)-trans-1-isopropyl-2,3,3,5-tetramethyl-6-succinylindane 0
                    (S,S)-trans-2-ethyl-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                    1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)-2-butanol 0
                    1-[2-[2-(2,3-dihydro-1H-inden-5-yloxy)ethoxy]ethyl]-1,2,4-triazole 0
                    2-(2,3-dichlorophenoxy)-N-(2,3-dihydro-1H-inden-5-yl)acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                    5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine 0
                    5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarbohydrazide 0
                    5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime 0
                    6-methoxy indan-5-ol 0
                    Aprindine hydrochloride 0
                    GDC-0879 0
                    ICI 118551 30
                    Indanestrol 0
                    LSM-10937 0
                    LSM-11498 0
                    LSM-9123 0
                    LSM-9318 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-2-[(2-nitro-3-pyridinyl)oxy]acetamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-2-methyl-3-nitrobenzamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamide 0
                    N-(2,3-dihydroinden-1-ylideneamino)-2,4-dimethylbenzamide 0
                    N-(2,3-dihydroinden-1-ylideneamino)-2-nitroaniline 0
                    N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine + 0
                    N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                    N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                    N-[(5-bromo-2-methoxyphenyl)methylideneamino]-5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarboxamide 0
                    N-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamide 0
                    N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide 0
                    allyl \{(1S)-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]-3-pyrrolidin-3-ylpropyl\}carbamate 0
                    aprindine 6
                    enrasentan 2
                    ethyl \{(1S)-5-amino-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]pentyl\}carbamate 0
                    glyhexamide 0
                    indacaterol 0
                    indan-1-ol + 3
                    indan-2-one oxime 0
                    indan-5-ol + 0
                    indanazoline 0
                    indane + 8
                    indanones + 4
                    inpyrfluxam 0
                    lignin cw compound-3045 0
                    pevonedistat 35
                    quadrangularin A 0
                    rasagiline 3
                    sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                    sulfamic acid [4-[4-(2,3-dihydro-1H-inden-1-ylamino)-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                    tolindate 0
                    traseolide + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19883
    subatomic particle 19881
      composite particle 19881
        hadron 19881
          baryon 19881
            nucleon 19881
              atomic nucleus 19881
                atom 19881
                  main group element atom 19771
                    p-block element atom 19771
                      carbon group element atom 19679
                        carbon group molecular entity 19679
                          organic molecular entity 19668
                            organic molecule 19596
                              organic cyclic compound 19407
                                carbocyclic compound 18312
                                  carbopolycyclic compound 17079
                                    carbobicyclic compound 5818
                                      indanes 83
                                        (1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine 0
                                        (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-2-phenylmethyl-4-hydroxy-5-[(2S)-4-(benzofuran-2-ylmethyl)-2-(tert-butylaminocarbonyl)piperazin-1-yl]pentanamide 0
                                        (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-5-[(2S)-2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(phenylmethyl)pentanamide 0
                                        (3R)-tetrahydrofuran-3-yl [(1S,2S)-1-benzyl-3-\{(2S)-2-benzyl-4-[(1R,2R)-2-(carbamoyloxy)-2,3-dihydro-1H-inden-1-yl]-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-2-hydroxypropyl]carbamate 0
                                        (3S)-tetrahydrofuran-3-yl [(1S,2S)-3-\{(2S)-4-[(1R,3R)-3-(2-amino-2-oxoethyl)-2,3-dihydro-1H-inden-1-yl]-2-benzyl-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-1-benzyl-2-hydroxypropyl]carbamate 0
                                        (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-3-(methylsulfonyl)-L-alanyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                                        (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                                        (R)-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                                        (S,S)-trans-1-isopropyl-2,3,3,5-tetramethyl-6-succinylindane 0
                                        (S,S)-trans-2-ethyl-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                                        1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)-2-butanol 0
                                        1-[2-[2-(2,3-dihydro-1H-inden-5-yloxy)ethoxy]ethyl]-1,2,4-triazole 0
                                        2-(2,3-dichlorophenoxy)-N-(2,3-dihydro-1H-inden-5-yl)acetamide 0
                                        2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                                        5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine 0
                                        5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarbohydrazide 0
                                        5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime 0
                                        6-methoxy indan-5-ol 0
                                        Aprindine hydrochloride 0
                                        GDC-0879 0
                                        ICI 118551 30
                                        Indanestrol 0
                                        LSM-10937 0
                                        LSM-11498 0
                                        LSM-9123 0
                                        LSM-9318 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-2-[(2-nitro-3-pyridinyl)oxy]acetamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-2-methyl-3-nitrobenzamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamide 0
                                        N-(2,3-dihydroinden-1-ylideneamino)-2,4-dimethylbenzamide 0
                                        N-(2,3-dihydroinden-1-ylideneamino)-2-nitroaniline 0
                                        N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine + 0
                                        N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                                        N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                                        N-[(5-bromo-2-methoxyphenyl)methylideneamino]-5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarboxamide 0
                                        N-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamide 0
                                        N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide 0
                                        allyl \{(1S)-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]-3-pyrrolidin-3-ylpropyl\}carbamate 0
                                        aprindine 6
                                        enrasentan 2
                                        ethyl \{(1S)-5-amino-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]pentyl\}carbamate 0
                                        glyhexamide 0
                                        indacaterol 0
                                        indan-1-ol + 3
                                        indan-2-one oxime 0
                                        indan-5-ol + 0
                                        indanazoline 0
                                        indane + 8
                                        indanones + 4
                                        inpyrfluxam 0
                                        lignin cw compound-3045 0
                                        pevonedistat 35
                                        quadrangularin A 0
                                        rasagiline 3
                                        sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                                        sulfamic acid [4-[4-(2,3-dihydro-1H-inden-1-ylamino)-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                                        tolindate 0
                                        traseolide + 0
paths to the root